The Effect Of Serum And Follicular Fluid Hypoxia İnducible Factor 1α On İnvitro Fertilization Outcomes İn Patients With Polycystic Ovary Syndrome

Abstract Objective: To investigate serum and follicular fluid (FF) HIF-1α levels in nonobese, nonhyperandrogenic patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF), in addition to IVF outcomes. Materials and Methods: A prospective sequential cross-sectional study carried at a Research and Education Hospital. In total, 160 patients undergoing IVF treatment were included in the study: 80 patients diagnosed with PCOS according to the Rotterdam criteria (group I, study) and 80 patients with the etiology of male factor infertility (group II, control). Results: There were statistically significant between-group differences in serum estradiol (E2) levels on the day of hCG administration (2,377.00 ± 733.23 versus 1,931.3 ± 1,010.69), the total gonadotropin dose required (2,000.63 ± 1,051.87 versus 1.134.69 ± 286.45), and the total number of retrieved oocytes (8.60 ± 2.06 versus 11.05 ± 4.39) (P < 0.05). There was also a statistically significant between-group difference in serum and FF HIF-1α levels on the day of oocyte retrieval (0.21 + 0.06 versus 0.17 + 0.04, P = 0.001; 0.09 + 0.05 versus 0.06 + 0.03 P = 0.007; respectively). Conclusions: In a selected population of nonobese, nonhyperandrogenic PCOS patients, there was a significant difference in HIF-1α levels of the PCOS group versus those of the control group. Further studies are needed to determine the effects of HIF-1α in women with PCOS and to develop a new marker to monitor treatment outcomes.

Erişime Açık
Görüntülenme
5
22.03.2024 tarihinden bu yana
İndirme
1
22.03.2024 tarihinden bu yana
Son Erişim Tarihi
19 Nisan 2024 21:48
Google Kontrol
Tıklayınız
Tam Metin
Tam Metin İndirmek için tıklayın Ön izleme
Detaylı Görünüm
Eser Adı
(dc.title)
The Effect Of Serum And Follicular Fluid Hypoxia İnducible Factor 1α On İnvitro Fertilization Outcomes İn Patients With Polycystic Ovary Syndrome
Yayın Türü
(dc.type)
Makale
Yazar/lar
(dc.contributor.author)
YÜCEL, Kamile
Atıf Dizini
(dc.source.database)
Wos
Atıf Dizini
(dc.source.database)
Scopus
Yayın Tarihi
(dc.date.issued)
2019
Kayıt Giriş Tarihi
(dc.date.accessioned)
2019-07-08T09:17:00Z
Açık Erişim tarihi
(dc.date.available)
2019-07-08T09:17:00Z
Özet
(dc.description.abstract)
Abstract Objective: To investigate serum and follicular fluid (FF) HIF-1α levels in nonobese, nonhyperandrogenic patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF), in addition to IVF outcomes. Materials and Methods: A prospective sequential cross-sectional study carried at a Research and Education Hospital. In total, 160 patients undergoing IVF treatment were included in the study: 80 patients diagnosed with PCOS according to the Rotterdam criteria (group I, study) and 80 patients with the etiology of male factor infertility (group II, control). Results: There were statistically significant between-group differences in serum estradiol (E2) levels on the day of hCG administration (2,377.00 ± 733.23 versus 1,931.3 ± 1,010.69), the total gonadotropin dose required (2,000.63 ± 1,051.87 versus 1.134.69 ± 286.45), and the total number of retrieved oocytes (8.60 ± 2.06 versus 11.05 ± 4.39) (P < 0.05). There was also a statistically significant between-group difference in serum and FF HIF-1α levels on the day of oocyte retrieval (0.21 + 0.06 versus 0.17 + 0.04, P = 0.001; 0.09 + 0.05 versus 0.06 + 0.03 P = 0.007; respectively). Conclusions: In a selected population of nonobese, nonhyperandrogenic PCOS patients, there was a significant difference in HIF-1α levels of the PCOS group versus those of the control group. Further studies are needed to determine the effects of HIF-1α in women with PCOS and to develop a new marker to monitor treatment outcomes.
Tek Biçim Adres
(dc.identifier.uri)
https://hdl.handle.net/20.500.12498/642
Analizler
Yayın Görüntülenme
Yayın Görüntülenme
Erişilen ülkeler
Erişilen şehirler
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve cerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms